PARS Projected Dividend Yield
Pharmos Corp. ( OTCBB : PARS )Pharmos is a biopharmaceutical company that discovers and develops therapeutics to treat metabolic and nervous system disorders, including gout, disorders of the brain-gut axis (e.g., Irritable Bowel Syndrome or IBS), pain/inflammation, and autoimmune disorders. Co. has two compounds in clinical development: Levotofisopam and Dextofisopam. Levotofisopam is the S-enantiomer of the racemic mixture RS-tofisopam, a non-sedating agent used outside the U.S. for the treatment of a variety of disorders related to stress or autonomic instability. Co. is developing Levotofisopam for the treatment of gout. Dextofisopam is the R enantiomer and is being developed for the treatment of IBS. 20 YEAR PERFORMANCE RESULTS |
PARS Dividend History Detail PARS Dividend News PARS Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |